A short clip from obesity doctor Nadolsky with his three pointers for people about to begin GLP-1 treatment. The details are in the video.
Recap by typeshit. Post by @drnadolsky on Instagram.
A short link post on what patients should keep in mind as options for semaglutide and tirzepatide keep shifting. Details are at the source.
A general explainer on how GLP-1 receptor agonists affect blood sugar and appetite, with advice on support while taking them.
A sponsored-style look at compounded tirzepatide and semaglutide through telehealth firm Mochi Health, noting compounded drugs aren't FDA approved for safety or quality.
Among the items: Walmart plans free GLP-1 diabetes drugs for employees in 2027, and Verdiva Bio dropped a phase II oral GLP-1 study citing market changes.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Alicia Butterfield claims Anthem denied her Zepbound once the drug got her below morbid obesity. A Los Angeles judge stayed her case pending arbitration.
Loading…